Skip to main content
logo
DiaSorin S.p.A. (VIE:DIAS)
Austria flag Austria · Delayed Price · Currency is EUR
77.20
+1.24 (1.63%)
At close: Oct 22, 2025

EBIT by Geography

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 20202010 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2010 - 2019
Italy Operating Profit
104.56M
Log In
Log In
Log In
Log In
Upgrade
Italy Operating Profit Growth
-22.58%
Log In
Log In
Log In
Log In
Upgrade
Europe Operating Profit
24.35M
Log In
Log In
Log In
Log In
Upgrade
Europe Operating Profit Growth
0.63%
Log In
Log In
Log In
Log In
Upgrade
North America Operating Profit
140.76M
Log In
Log In
Log In
Log In
Upgrade
North America Operating Profit Growth
-27.79%
Log In
Log In
Log In
Log In
Upgrade
Rest of the World Operating Profit
1.27M
Log In
Log In
Log In
Log In
Upgrade
Rest of the World Operating Profit Growth
-1957.49%
Log In
Log In
Log In
Log In
Upgrade
Eliminations from Operating Profit
-12.61M
Log In
Log In
Log In
Log In
Upgrade
Eliminations from Operating Profit Growth
-204.00%
Log In
Log In
Log In
Log In
Upgrade

Revenue by Geography

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 20202010 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2010 - 2019
Italy
176.52M
Log In
Log In
Log In
Log In
Upgrade
Italy Growth
-11.51%
Log In
Log In
Log In
Log In
Upgrade
Europe
288.15M
Log In
Log In
Log In
Log In
Upgrade
Europe Growth
4.93%
Log In
Log In
Log In
Log In
Upgrade
North America
618.94M
Log In
Log In
Log In
Log In
Upgrade
North America Growth
-16.25%
Log In
Log In
Log In
Log In
Upgrade
Rest of the World
101.81M
Log In
Log In
Log In
Log In
Upgrade
Rest of the World Growth
-9.70%
Log In
Log In
Log In
Log In
Upgrade

Other

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 20202010 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2010 - 2019
Ex-COVID Immunodiagnostics % of Revenue
66.20
Log In
Log In
Log In
Log In
Upgrade
Ex-COVID Immunodiagnostics % of Revenue Growth
-
Log In
Log In
Log In
Log In
Upgrade
Ex-COVID Molecular Diagnostics % of Revenue
17.20
Log In
Log In
Log In
Log In
Upgrade
Ex-COVID Molecular Diagnostics % of Revenue Growth
-
Log In
Log In
Log In
Log In
Upgrade
Licensed Technologies % of Revenue
14.40
Log In
Log In
Log In
Log In
Upgrade
Licensed Technologies % of Revenue Growth
-
Log In
Log In
Log In
Log In
Upgrade
COVID % of Revenue
2.20
Log In
Log In
Log In
Log In
Upgrade
COVID % of Revenue Growth
-
Log In
Log In
Log In
Log In
Upgrade